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Abstract
Transdermal drug delivery has made a notable contribution to medical practice, but has yet to fully achieve its potential as
an alternative to oral delivery and hypodermic injections. While transdermal delivery systems would appear to provide an
attractive solution for local and systemic drug delivery, only a limited number of drugs can be delivered through the outer
layer of the skin. The most difficult to deliver in this way are hydrophilic drugs. The aquatic phylum Cnidaria, which includes
sea anemones, corals, jellyfish and hydra, is one of the most ancient multicellular phyla that possess stinging cells
containing organelles (cnidocysts), comprising a sophisticated injection system. The apparatus is folded within collagenous
microcapsules and upon activation injects a thin tubule that immediately penetrates the prey and delivers its contents. Here
we show that this natural microscopic injection system can be adapted for systemic transdermal drug delivery once it is
isolated from the cells and uploaded with the drug. Using a topically applied gel containing isolated natural sea anemone
injectors and the muscarinic receptor antagonist scopolamine, we found that the formulated injectors could penetrate
porcine skin and immediately deliver this hydrophilic drug. An in-vivo study in pigs demonstrated, for the first time, rapid
systemic delivery of scopolamine, with Tmax of 30 minutes and Cmax 5 times higher than in controls treated topically with a
scopolamine-containing gel without cnidocysts. The ability of the formulated natural injection system to penetrate a barrier
as thick as the skin and systemically deliver an exogenous compound presents an intriguing and attractive alternative for
hydrophilic transdermal drug delivery.
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Introduction
Transdermal delivery has advantages over conventional drug
delivery systems in that it reduces first-pass metabolism, eliminates
drastic drug fluctuations, prevents adverse side effects, and increases
patient compliance. A variety of vehicles and technologies have been
developed to penetrate the skin barrier [1], allowing transcutaneous
drug delivery [2,3]. The two main approaches employed to augment
skin permeability and penetration are based on utilization of passive
chemical enhancers or advanced active physical energetic devices.
The passive approach includes the use of different types of topical
formulations, including chemical enhancers, liposomes, ethosomes,
or large reservoir-type patches [4,5]. However, while these
technologies have the advantage of high patient compliance, they
usually require a prolonged application time and are limited to
molecules that are both lipophilic and small. The physical approach
primarily employs high-energy devices such as needle-free injectors,
low-frequency ultrasound, iontophoresis, electroporation, micronee-
dles, or thermal procedures [6,7]. These advanced methods have the
advantage of rapidly permeating the skin barrier, but they generally
entailsophisticateddevices,professionaladministration,highercosts,
and lower patient compliance. Owing to these limitations relatively
few drugs can currently be introduced transdermally, with particular
difficulty experienced in the delivery of hydrophilic drugs through
this route [8].
The phylum Cnidaria, dated to around 700 million years ago,
typically features stinging cells containing cnidocysts, microcap-
sules equipped with a submicron injection system [9,10].
Activation of the microcapsule engenders a high internal pressure
of 150 bars, resulting in the discharge of a long folded tubule at an
ultrafast acceleration of 5610
6 g [11,12]. About 30 subtypes of
cnidocysts are known. They differ in size and shape, but all
function according to the same basic principle (Fig. 1). Discharge
of the system is controlled by osmotic balance. Once the system is
activated, water flows through the porous cnidocyst wall causing
dissociation of a large aggregated matrix of poly-c-glutamate
trapped by cationic metal. This in turn increases the osmotic
pressure, resulting in ejection of the tubule [12,13,14]. The poly-c-
glutamate matrix serves as the internal ‘‘battery’’ of the system and
this, together with the high tensile strength of the cnidocyst wall
[15], can build up the pressure required to propel the tubule out at
an acceleration high enough to puncture the skin of the targeted
prey and immediately deliver the cnidocyst content [16]. We have
previously shown that the sea anemone micro-injection system can
be applied for topical delivery, is compatible with hydrophilic
compounds, and is clinically safe [16,17,18].
The aim of the present study was to evaluate the potential use of
the cnidocyst system as an active vehicle for systemic drug delivery.
The drug of choice was scopolamine, as its delivery profile in
topical applications is well documented. The animal model we
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1chose was the pig, as it is similar to humans in its anatomy,
genetics, physiology and biochemistry, and is well recognized as an
experimental animal in biomedical research [19,20]. It is a
particularly reliable model for transdermal research in vivo because
its skin is highly similar to human skin in having low hairiness, a
thick strateum corneum, and similar dermis composition, as
comprehensively reviewed by Simon and Maibach [21]. Using a
porcine model, we compared the pharmacokinetic profile of
scopolamine following a single topical application of the cnidocyst
system to that of a control topical application without cnidocysts.
Materials and Methods
Ethics Statement
All animals in the study were handled according to the
guidelines for efficacy testing of veterinary medical products
(Rules Governing Medicinal Products in the European Union,
Volume 7). The experiment protocol was approved by the Animal
Care Committee of the Experimental Institute of the Veterinary
Faculty of the Szent Istva ´n University, Hungary. The ID number
was PCG-206.
Chemicals and Formulations
Scopolamine hydrobromide solution (scopolamine HBr) and all
reagents were purchased from Sigma-Aldrich (Israel) unless stated
otherwise, and were of at least analytical grade. Acetonitrile
(HPLC grade) and ethanol were purchased from Riedel de Haen
(Seelze, Germany). KlucelH HF Pharm hydroxypropylcellulose
(HPC) was received from Hercules Aqualon (Wilmington, DE,
USA). The control gel formulation contained 2% HPC in absolute
ethanol. The cnidocyst gel contained 0.075610
6 microcapsules/





The sea anemone Aiptasia diaphana, when triggered mechani-
cally, secretes thin filaments (acontia) enriched with microcapsules
(Fig. 2). We exploited this natural behavior to obtain filaments
without harming the anemone. Microcapsules were isolated from
the filamentous tissue as described previously [16,22,23]. Briefly,
filaments were incubated in 1 M sodium citrate, followed by two
centrifugations in 70% Percoll gradients. The isolated microcap-
sules were washed with decreasing concentrations of NaCl (1 M to
0.2 M) and freeze-dried. The purified microcapsules were kept as
a lyophilized powder until use.
In-vitro Permeability Tests
Tape-stripping assay. Isolated porcine ear skins were
covered with cnidocyst gel, and 0.05% toluidine blue dye
solution was then added. After 5 minutes the treated sites were
rinsed with distilled water, gently wiped to remove the applied
materials, and photographed. To examine dye permeability the
skin was tape-stripped 30 times to remove the stratum corneum
and the residual skin was photographed under a Zeiss Axioskop 40
microscope.
Franz diffusion cell and HPLC analysis. Permeability of
scopolamine HBr 5% solution through the full skin of 8-week-old
female nude mice (CD1 strain) was measured in vitro in a Franz
diffusion cell system as previously described [16]. In brief,
cnidocyst gel (8 mg) was introduced into the donor chambers on
the skin and overlaid with excess of scopolamine HBr 5% solution.
As a control, skin pieces were covered with 8 mg of gel without
cnidocysts, and overlaid with the same scopolamine HBr solution.
After 5 minutes the scopolamine HBr solution was removed and
the embedded skins in the Franz cell apparatus were thoroughly
washed 5 times with Millipore DDW. The skins were then left in
the diffusion cell for up to 24 h to allow the delivered drug to
diffuse under the skin. During that period, samples (2 ml) were
taken from the receiver compartment after 0.5, 1, 1.5, 3, 5, and
23–24 h, and after each withdrawal the receiver was filled with
fresh saline solution. The samples were analyzed by HPLC
(Hewlett Packard LC1090 Liquid Chromatograph with a diode-
array detector). The analysis was performed at room temperature
using a 5-mm Kromasil Cyano column (KR60-5CN;
25064.6 mm). The mobile phase consisted of 68% (A) 20%
acetonitrile in 20 mM, pH 6 phosphate buffer, and, 32% (B)
Acetonitrile. The flow rate was 1.2 ml/min and the UV detector
was set at a wavelength of 210 nm. The injection volume was
40 ml and scopolamine retention time was 7.5 minutes [24,25].
Data were expressed as the cumulative scopolamine permeation
per square centimetre of skin surface.
In-Vivo Study in Pigs
Seven white Landrance pigs, each weighing approximately
20 kg, were sedated with ketamine (100 mg/ml) and medetomi-
dine (DomitorH, Pfizer; 1 mg/ml). The animals were injected
intramuscularly with a combination of these two drugs (0.6–
0.7 ml/kg body weight), giving approximately 30 minutes of
sedation. Four pigs (labelled 4–7A) were topically treated with the
cnidocyst gel containing 1610
6 cnidocysts/cm
2 and 5% scopol-
amine HBr, and three with the control gel (without cnidocysts)
(labelled 1–3A) and 5% scopolamine HBr. The back of each
animal was gently shaved 24 h before the start of the experiment.
A 15-cm
2 application area on the shaved back was then rinsed
Figure 1. Mode of action of the cnidocyst system. The intact dry
cnidocyst (a) is activated by the hydrophilic drug solution (b) water
molecules (blue triangle) and the soluble drug (green circles) penetrate
the porous wall of the cnidocyst, resulting in discharge of the tubule and
injection of its microcapsule content through the tubule to the skin (c).
doi:10.1371/journal.pone.0031922.g001
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application site. Test or control gel preparations (190 mg) were
applied, followed by immediate application of excess of scopol-
amine HBr. After 5 minutes the treated sites were washed with
distilled water and gently wiped to remove the applied product.
From each pig, 12 blood samples were obtained via the
antebrachial cephalic sinus. The first sample was obtained
immediately before the topical dose application and the rest were
collected 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h afterwards.
Scopolamine concentrations were assayed using a validated liquid
chromatography–mass spectrometry (LC–MS/MS(+)) method
with a lower limit of quantification of 10.4 ng/l [26]_ENRE-
F_15_ENREF_15._ENREF_15_ENREF_15 The HPLC system
was equipped with a Merck LiChrospher 100 RP select B, 5 mm
(4675 mm) column and an MS/MS Sciex API 4000 detector.
Pharmacokinetic evaluations of Cmax,T max, half-life elimination
time (t1/2) and area under the concentration curve (AUC) were
calculated using WinNonlin (Pharsight) pharmacokinetic software.
No abnormal or adverse physiological effects were observed in any
of the animals.
Results
Preparation of Cnidocysts for Drug Delivery
We used the naturally secreted acontial filaments of the sea
anemone Aiptasia diaphana, which are highly enriched with
cnidocysts (Fig. 2a). Cnidocysts were isolated from the filaments
by exploiting their high density and high stability in salts, and were
then freeze-dried. An isolated microcapsule preparation contained
one type of intact cylindrical microcapsule, 60 mm in length and
8 mm in diameter, with a 150-mm-long injector folded within
(Fig. 2b). The injector is composed of two main parts: a 100-mm-
long shaft containing barbs and a 50-mm-long smooth tubule with
a diameter smaller than 1 mm (Fig. 2c). The isolated preparation
was kept dry and did not lose its potential discharge characteristics
[16]. Prior to its application over the skin the preparation was
formulated into an anhydrous gel consisting of 2% hydroxyl
propyl cellulose in absolute ethanol. This gel formulation kept the
cnidocysts in close contact with the skin, but did not trigger their
discharge. Activation of the microcapsules occurred only when
they were exposed to the hydrophilic solution.
Immediate Delivery to Viable Epidermis
To determine whether the isolated cnidocysts could penetrate
porcine skin and deliver an exogenous hydrophilic compound to
the viable epidermis, the cnidocyst gel was applied in vitro over an
isolated piece of porcine skin and the preparation was activated
with a hydrophilic solution containing 0.05% toluidine blue dye
solution. Five minutes after activation the skin was thoroughly
washed and the stratum corneum was removed (Fig. 3a and b).
The results showed that the isolated cnidocysts had penetrated the
stratum corneum and delivered the dye to the viable epidermis
within 5 minutes of activation. Thus, the isolated system had
retained its natural properties and the rehydration had been
sufficient to trigger its activation.
In-Vitro Delivery of Scopolamine
To obtain quantitative results of a short application of the
cnidocyst gel, we used the Franz diffusion cell system to measure
the amount of the potent muscarinic receptor antagonist
scopolamine delivered in vitro through the full-thickness skin of a
nude mouse. We chose this preparation as it is a convenient and
readily available model for percutaneous penetration [27], and has
been found to serve as a suitable skin model for testing cnidocyst
system quantitative delivery [16]. The cnidocyst gel was applied
for 5 minutes on the skin with 5% scopolamine as in the dye
experiment. HPLC analysis revealed rapid and active drug
delivery by the cnidocyst gel (Fig. 4). The amount of scopolamine
delivered to the skin was 78.2627 mg/cm
2, whereas in control skin
samples that received gel without cnidocysts the amount of
scopolamine delivered was negligible (0.9961.1 mg/cm
2).
Pharmacokinetics of Scopolamine
The ability of the natural injectors to deliver scopolamine in vivo
was tested in a porcine model. The experiment was performed on
seven pigs, four of which (experimental group) were treated with
the topically applied gel containing cnidocysts, while the other
three (control group) received the gel without cnidocysts. Both
groups were exposed to 5% scopolamine solution for only
Figure 2. Preparation of cnidocysts. (a) A filament of Aiptasia diaphana containing packed cnidocysts. Bar, 100 mm. (b) Isolated cnidocysts. Bar,
25 mm. (c), A discharging cnidocyst. Following release of the folded 150-mm injector, only its smooth tip (50 mm long, submicron diameter) can
penetrate the skin (see arrow). Bar, 25 mm.
doi:10.1371/journal.pone.0031922.g002
Figure 3. In-vitro delivery of hydrophilic compounds by
cnidocysts in a gel formulation. (a) Activation of cnidocyst gel
over isolated porcine ear skin with 0.05% toluidine blue dye solution for
5 min. Following application the skin was thoroughly washed and then
photographed. Black arrows, penetrating cnidocyst. White arrow, skin
hair bundle. Scale bar, 100 mm. (b) The skin was tape-stripped 30 times
to remove the stratum corneum and then photographed. Scale bar,
100 mm.
doi:10.1371/journal.pone.0031922.g003
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Table 1 presents the scopolamine pharmacokinetic parameters
calculated from the blood samples collected from each pig,
reflecting the ability of the natural injectors to deliver scopolamine
systemically. Peak plasma concentrations (Cmax) were up to five
times higher, on average, in the experimental group than in the
control group (5006258 pg/ml compared to 133631 pg/ml;
Fig. 5). In addition, the time to maximal concentration (Tmax) was
significantly shorter in the experimental group than in the control
(0.560 h compared to 2.761.5 h), and the average area under the
concentration curve (AUC0–24), representing the mean drug
concentration in the body, was nearly two fold higher for the
experimental group than for the control. No adverse or abnormal
effects were observed in the pigs during the experimental
procedure. Thus, although the drug delivery route was topical,
the injection system tested in this study had a relatively short onset
time and enabled the drug to accumulate rapidly in the plasma.
Discussion
In this report we describe a naturally derived system, isolated
from sea anemone, that operates as a submicron injection system
and was used here as micro devices in topical application for
delivery of the hydrophilic drug scopolamine. We showed that
short (5 minutes) exposure of this system to hydrophilic compound
is sufficient to facilitate delivery of the drug to viable pig epidermis.
Successful systemic targeting of the topically applied scopolamine
by this natural system in vivo was demonstrated here, for the first
time, in a pharmacokinetic study that revealed a significantly
shorter Tmax (30 min) and a Cmax up to 5 times higher than in the
control.
Scopolamine, a naturally occurring alkaloid, is one of the most
effective single agents used to prevent motion sickness [28] and is
also commonly used for the prevention of postoperative nausea
and vomiting [29]. Being a tertiary amine scopolamine hydrobro-
mide diffuses passively through the blood-brain barrier; thus, its
oral or parenteral administration results in enhanced severity of
the drug’s adverse effects, which may include visual disturbances,
dizziness, agitation, dry mouth, hallucinations, amnesia and
drowsiness [28]. Moreover, scopolamine intoxication is dose-
dependent, and in addition to its short half-life in plasma, its oral
or parenterally administration is more limited in clinical use [30].
Hence, the preferred mode of delivery is the transdermal route,
which exhibits relatively low scopolamine toxicity manifested
mainly with limited visual disturbances and dry mouth [29,31].
Scopolamine was among the first drugs to be incorporated into a
transdermal patch. When administered in that form, however, the
drug does not exert its effect until 6 to 8 hours after patch
application because of its characteristic slow, incremental
transdermal diffusion [29,32,33]. Moreover, it was suggested that
Figure 4. Scopolamine 5-minute in-vitro study. Cumulative
permeation of scopolamine delivered by cnidocyst gel (n=11)
compared to control gel without microcapsules (n=5) after 24 hours.
Error bars represent s.d.
doi:10.1371/journal.pone.0031922.g004
Figure 5. Plasma levels of scopolamine in pigs after short
topical exposure. Test and control groups were exposed for
5 minutes to the same solution of 5% scopolamine HBr. Averaged
values (means 6 s.d) of the test group (&) treated with gel formulation
containing isolated cnidocysts and of the control group (D) treated with
gel formulation only.
doi:10.1371/journal.pone.0031922.g005
Table 1. Calculated pharmacokinetic parameters of scopolamine in pig plasma after a 5-minute topical application of the drug.
Parameter* Units Pig No.
Control group Experimental group (Cnidocysts) Preparation
1A 2A 3A 4A 5A 6A 7A
Cmax pg/ml 155 98.4 148.4 419.5 855.3 239.5 486.6
Tmax hours 3.0 4.0 1.0 0.5 0.5 0.5 0.5
t1/2 hours 4.4 6.8 9.7 5.2 5.6 4.8 7.1
AUC0–24 hours(pg/ml) 1191.5 911.5 816.1 1973.0 2488.9 970.1 1155.3
AUCINF hours(pg/ml) 1316.9 1028.7 946.5 2320.8 2628.7 1093.1 1289.9
*Cmax, peak plasma concentration; Tmax, time to maximal concentration; tK, half-life elimination time; AUC, Area under the plasma concentration time curve.
doi:10.1371/journal.pone.0031922.t001
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plasma, the patch system should be combined with oral
administration [32,34]. With the natural injection system de-
scribed here, however, the drug was delivered immediately to the
skin and the time taken to accumulation in the plasma was
relatively short. Thus, despite its topical formulation, the
pharmacokinetic characteristics of the drug were comparable to
those reported for its subcutaneous injection [30]. Furthermore,
topical application enjoys the additional advantages of ease of
administration and hence better patient compliance. In this study
we tested the effect of a single application of scopolamine using a
selected microcapsule number and drug dose. We have previously
shown, however, that the concentration of the delivered drug can
be controlled by changing either the number of microcapsules or
the drug concentration [16,17]. Thus, when other drugs are used,
these parameters need to be adjusted accordingly and additional
doses added if necessary.
The natural injection system described here combines the
benefits of chemical and physical transdermal technologies, both
in the simplicity of its use and its rapid delivery mechanism. The
technology that most closely resembles the cnidocyst delivery
system is delivery by fabricated microneedles. Several sophisticat-
ed microneedle systems have been developed over the last decade
[3,7,8,35,36,37]. Most of them are drug-coated projections that
pierce the skin to create pores, and in combination with a patch or
other transdermal method, facilitate drug delivery. Others are
active flow delivery devices composed of hollow needles. However,
skin penetration by solid or hollow microneedles is critically
dependent on the pressure applied to the microneedles array [3].
Thus for example, to achieve uniform pressure for insertion of the
microneedle tip into the skin, application of the microneedle array
requires that external energy be provided by an applicator device
[35,38,39].
In contrast, the high energy needed to shoot a cnidocyst injector
into the skin and pump the drug through the hollow tubule is a
built-in feature of the isolated intact microcapsule. Therefore, no
external energy is required and the microcapsules can be
incorporated in a user-friendly gel that is easy to apply.
Furthermore, safety trials conducted in more than 100 human
volunteers demonstrated no irritation or allergenicity caused by
the injection system [16,18]. In addition, in a swine study, gentle
wiping of the treatment site after application sufficed to remove
the injectors from the skin, and in unwiped sites only traces of the
injectors were found after 2 days [17]. The potential of the system
lies also in its flexibility and modularity, since a wide range of
different hydrophilic compounds can be attached to the basic gel
containing the cnidocysts and used in different therapeutic
contexts. Taken together, the above findings suggest that the
natural injection technology offers an intriguing and attractive
option for fast-acting hydrophilic transdermal drug delivery.
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